AI assistant
ICONIC LABS PLC — AGM Information 2020
Feb 27, 2020
4953_rns_2020-02-27_7df14998-e640-44dc-be9b-73475c0eb9b2.pdf
AGM Information
Open in viewerOpens in your device viewer
Iconic Labs PLC 27 February 2020
Iconic Labs Plc ("Iconic Labs" or the "Company") Results of General Meeting
Iconic Labs plc (AIM: ICON), a multi-divisional new media and technology business, advises that it held a General Meeting (" GM") earlier today.
All resolutions were duly passed on a poll vote. Details of the proxy voting are shown in the table below.
| Resolutions | Votes For | % | Votes Against |
% | Votes Total | Votes Withheld |
|---|---|---|---|---|---|---|
| 1 Authority to sub-divide shares and adopt new articles |
153,111,913 88.11 20,665,281 11.89 173,777,194 1,500,000 | |||||
| (Special Resolution) |
||||||
| 2 Authority to issue notes and warrants under Deed of Issuance and Financing and Settlement Agreement |
153,111,913 88.11 20,665,281 11.89 173,777,194 1,500,000 | |||||
| (Ordinary Resolution) |
||||||
| 3. Empowering the directors' to disapply statutory pre-emption rights |
152,498,075 87.75 21,279,119 12.25 173,777,194 1,500,000 | |||||
| (Special Resolution) |
The Company also acknowledges the continual concerns raised by shareholders as to the underlying identity of the holders of its shares and the need for the Company to publish an accurate updated shareholder register. To that end, the Company issued notices to several shareholders pursuant to its articles requiring disclosure of underlying beneficial holders. In accordance with the articles, such shares are disenfranchised until the shareholder complies with the notice.
Iconic Labs PLC
For information please contact:
Damon Heath Shard Capital Partners LLP Tel: +44 (0) 20 7186 9950
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contac[email protected] or visit www.rns.com.
END